Posts by: Iqra Mumal, PhD

Iqra Mumal, PhD

April 12, 2019April 12, 2019

Long-term Use of Oral Contraceptives Protects Against Deadliest Forms of Ovarian Cancer, Large Study Finds

News

Long-term use of oral contraceptives protects women from the most lethal types of ovarian cancers, a large multi-center study has found. The study, “Oral contraceptive use and risk of ... Read more

September 17, 2018

Two-pronged Antibody Can Help Efficiently Destroy Ovarian Cancer Cells, Researchers Find

News

A newly developed two-pronged antibody is 100 times more effective at destroying ovarian cancer cells than other antibodies in clinical trials, according to researchers at the University of Virginia ... Read more

July 23, 2018

Post-diagnosis Use of Anti-Inflammatory Meds May Improve Ovarian Cancer-specific Survival, Study Suggests

News

Regular use of anti-inflammatory medication, such as aspirin, after an ovarian cancer diagnosis appears to improve ovarian cancer-specific survival, a study shows. The study, “Pre-diagnosis and post-diagnosis use of ... Read more

May 18, 2018

Protein Levels Could Replace Genetic Tests for Detecting ARID1A Mutations

News

A laboratory technique that measures protein levels in tissue samples — called immunohistochemistry (IHC) — is a quicker and less expensive alternative to detect ARID1A mutations in patients with ovarian and ... Read more

March 7, 2018March 7, 2018

Protein’s Expression on Immune Cells May Predict Response to Immunotherapy, Study Shows

News

Expression of a certain protein on two types of immune cells could help predict which cancer patients will respond to a specific immunotherapy, a study shows. The study, “Host expression ... Read more

December 4, 2017December 4, 2017

Long Non-coding RNAs Found Linked to Ovarian Cancer Metastasis, Study Shows

News

Researchers have found a set of long non-coding RNAs (lncRNAs) – RNA molecules with no protein-coding capacity – that participate in the metastatic process of ovarian cancer cells. Inhibiting ... Read more

November 8, 2017

Study Examines Chemotherapy Options for Partially Platinum-Sensitive OC Patients

News

Platinum-based chemotherapy (PBC) should be not be delayed in favor of non-platinum-based chemotherapy (NPBC) in patients with partially platinum-sensitive ovarian cancer, a new study shows. The study, “Randomized Controlled ... Read more

September 29, 2017September 29, 2017

Acelarin-Paraplatin Combo Shows High Disease Control Rates in Phase 1b Trial for Ovarian Cancer

News

Nearly all ovarian cancer patients enrolled in NuCana‘s Phase 1b trial benefited from the combination of Acelarin (NUC-1031) plus Paraplatin (carboplatin), according to data presented at the recent European ... Read more

August 23, 2017

Biotech Completes Dose Escalation Part of Phase 1 Study of COTI-2 in Gynecological Cancers

News

The dose escalation part of a Phase 1 trial evaluating COTI-2 in women with advanced gynecological cancers who did not respond to standard therapy has been completed, according to ... Read more

Pin It on Pinterest